Recovery in Revenue, Operating Profit and Net Income
First written in FY2016. 13 of 37 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-08-06.
Zeria Pharmaceutical moved to the "Worse" side of this theme in 2019, 2 years before the typical company in this theme (2021).
The whole theme swung hardest in 2018: 2 of 11 companies on the "Worse" side.
4 other companies' latest entry also says "Other".
- 2026-08-06OtherEarnings
「当第１四半期連結累計期間の売上高は214億48百万円（前年同四半期比10.1％増）、営業利益は19億50百万円（前年同四半期比28.3％増）となりました。一方、ユーロ、英ポンドなどの欧州通貨に対するスイスフラン高の進行などに伴い為替差損が発生したことから、経常利益は14億32百万円（前年同四半期比13.8％減）、親会社株主に帰属する四半期純利益は８億66百万円（前年同四半期比20.6％減）となりました。」
売上高・営業利益は増加した一方、為替差損の発生により経常利益・親会社株主に帰属する四半期純利益は減少した。 - FY2026Higher revenue and operating profit, lower ordinary profit and net incomeAnnual report
「As a result of these activities, net sales for the fiscal year were ¥89,159 million, up 2.1% year on year, and operating income was ¥12,374 million, up 1.4%. Ordinary income was ¥11,043 million, down 14.0%, as the company recorded a foreign exchange loss in the current period compared with a foreign exchange gain in the previous period. Net income attributable to owners of the parent was ¥8,454 million, down 14.9%.」
For the full year, net sales and operating income increased, while ordinary income and net income attributable to owners of the parent declined due to the shift from a foreign exchange gain to a foreign exchange loss. - FY2026-H1WorsenedAnnual report
「Net sales for the interim consolidated period were ¥39,960 million, down 5.8% year on year. Operating income was ¥3,641 million, down 43.6%, due to the decline in sales and higher expenses, including costs and investments in core systems at overseas subsidiaries. Although the company recorded a substantial foreign exchange gain of approximately ¥1.3 billion in the previous period, it recorded a foreign exchange loss of approximately ¥1.0 billion in the current period. As a result, ordinary income was ¥2,656 million, down 66.6% year on year, and interim net income attributable to owners of the parent was ¥1,737 million, down 71.3%.」
The interim period saw lower sales, lower operating income, lower ordinary income, and lower net income. Higher costs and expenses, including investments in core systems at overseas subsidiaries, together with the shift from a foreign exchange gain to a foreign exchange loss, weighed on earnings. - FY2025AdvancedAnnual report
「As a result of these activities, net sales for the fiscal year were ¥87,311 million, up 15.3% year on year, and operating income was ¥12,197 million, up 26.8%. Ordinary income was ¥12,840 million, up 50.8%, as the company recorded a foreign exchange gain in the current period compared with a substantial foreign exchange loss in the previous period. Net income attributable to owners of the parent was ¥9,936 million, up 28.5%, as the company recorded extraordinary losses, including impairment losses on investment securities, in the current period compared with extraordinary gains in the previous period.」
For the full year, net sales, operating income, ordinary income, and net income attributable to owners of the parent all increased year on year, further advancing the recovery and expansion of past business performance. - FY2025-H1AdvancedAnnual report
「Net sales for the interim consolidated period were ¥42,422 million, up 15.7% year on year. Operating income was ¥6,459 million, up 21.2%; ordinary income was ¥7,949 million, up 44.6%; and interim net income attributable to owners of the parent was ¥6,061 million, up 12.3%.」
Net sales, operating income, ordinary income, and interim net income attributable to owners of the parent all increased year on year in the interim period. - FY2024AdvancedAnnual report
「As a result of these activities, net sales for the fiscal year were ¥75,725 million, up 10.7% year on year. Operating income was ¥9,621 million, up 6.7%; ordinary income was ¥8,513 million, up 12.3%; and net income attributable to owners of the parent was ¥7,731 million, up 24.8%.」
For the full year, net sales, operating income, ordinary income, and net income attributable to owners of the parent all increased year on year. - FY2024-Q2Continued higher sales, lower operating income, higher ordinary income, and higher net incomeAnnual report
「Net sales for the cumulative second-quarter period were ¥36,678 million, up 8.8% year on year. Operating income, however, was ¥5,327 million, down 9.6%, due to higher expenses resulting from changes to part of the UK pharmaceutical price regulation system, as well as increases in sales promotion expenses and depreciation. Ordinary income and below increased because, although the company recorded a substantial foreign exchange loss in the previous period due to the rapid appreciation of the Swiss franc, it recorded a small foreign exchange gain in the current period. Ordinary income was ¥5,495 million, up 6.1% year on year, and net income attributable to owners of the parent was ¥5,396 million, up 35.0%, partly because the company recorded a reversal of the provision for contract termination losses as an extraordinary gain.」
Net sales increased, while operating income declined due to changes to the UK pharmaceutical price regulation system and higher sales promotion expenses and depreciation. Ordinary income and net income attributable to owners of the parent increased due to the shift to a foreign exchange gain and the reversal of the provision for contract termination losses. - FY2024-Q1Higher Revenue and Lower Operating Profit, Higher Ordinary ProfitAnnual report
「Net sales for the cumulative first-quarter period were ¥18,304 million, up 12.3% year on year. Operating income, however, was ¥2,970 million, down 0.2%, due to higher expenses, including sales promotion expenses, research and development expenses, and depreciation. Ordinary income and below increased because, although the company recorded a foreign exchange loss in the previous period due to the rapid appreciation of the Swiss franc, it recorded a foreign exchange gain in the current period. Ordinary income was ¥3,355 million, up 12.8% year on year, and net income attributable to owners of the parent was ¥2,915 million, up 12.1%.」
Net sales increased, while operating income declined slightly due to higher expenses. Ordinary income and net income attributable to owners of the parent increased, partly due to the recording of a foreign exchange gain. - FY2023AdvancedAnnual report
「As a result of these activities, net sales for the fiscal year were ¥68,383 million, up 14.9% year on year. Operating income was ¥9,014 million, up 41.6%; ordinary income was ¥7,579 million, up 27.7%; and net income attributable to owners of the parent was ¥6,195 million, up 56.4%.」
Full-year revenue, operating income, ordinary income, and net income attributable to owners of the parent all increased year on year. - FY2023-Q3AdvancedAnnual report
「Net sales for the cumulative third-quarter period were ¥51,729 million, up 14.7% year on year. Operating income was ¥8,550 million, up 55.6%; ordinary income was ¥6,957 million, up 24.0%; and net income attributable to owners of the parent was ¥5,980 million, up 47.9%.」
For the nine-month period, revenue, operating profit, ordinary profit and profit attributable to owners of the parent all increased year on year. - FY2023-Q2AdvancedAnnual report
「Revenue for the second quarter of the current consolidated cumulative period was ¥33,712 million, up 17.9% year on year. Operating profit was ¥5,894 million, up 120.6%; ordinary profit was ¥5,182 million, up 66.3%; and quarterly net income attributable to owners of the parent was ¥3,998 million, up 89.0%.」
For the cumulative second-quarter period, net sales, operating income, ordinary income, and net income attributable to owners of the parent all increased year on year. - FY2023-Q1AdvancedAnnual report
「Revenue for the first quarter of the current consolidated cumulative period was ¥16,305 million, up 20.3% year on year. Operating profit was ¥2,977 million, up 137.8%; ordinary profit was ¥2,974 million, up 42.9%; and quarterly net income attributable to owners of the parent was ¥2,601 million, up 84.6%.」
In the first quarter, revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent all increased year on year. - FY2022-Q3AdvancedAnnual report
「Revenue for the third quarter of the current consolidated cumulative period was ¥45,104 million, up 11.7% year on year. Operating profit was ¥5,495 million, up 41.6%; ordinary profit was ¥5,613 million, up 57.6%; and quarterly net income attributable to owners of the parent was ¥4,043 million, up 9.2%.」
Revenue and profit increased in the first three quarters, with revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent all increasing year on year. - FY2022-Q2AdvancedAnnual report
「Revenue for the second quarter of the current consolidated cumulative period was ¥28,606 million, up 12.1% year on year. Operating profit was ¥2,672 million, up 67.2%; ordinary profit was ¥3,116 million, up 138.4%; and quarterly net income attributable to owners of the parent was ¥2,115 million, up 52.4%. The increases in ordinary profit and below were due to higher revenue and substantial foreign exchange gains resulting from the continued depreciation of the Swiss franc against European currencies such as the pound sterling and euro.」
Revenue, operating profit, ordinary profit and net income all increased year on year. The increases in ordinary profit and below were supported by higher revenue and foreign exchange gains resulting from the depreciation of the Swiss franc. - FY2022-Q1Higher revenue and profit, with ordinary profit also boosted by foreign exchange gainsAnnual report
「Revenue for the first quarter of the current consolidated cumulative period was ¥13,548 million, up 6.4% year on year. Operating profit was ¥1,251 million, up 18.3%; ordinary profit was ¥2,081 million, up 229.1%; and quarterly net income attributable to owners of the parent was ¥1,408 million, up 44.8%.」
Revenue, operating profit, ordinary profit and net income all increased year on year. The increase in ordinary profit and below was supported by substantial foreign exchange gains resulting from the depreciation of the Swiss franc against European currencies. - FY2021-Q3Lower revenue, higher operating profit and higher net incomeAnnual report
「Revenue for the third quarter of the current consolidated cumulative period was ¥42,374 million, down 8.5% year on year. Operating profit was ¥3,856 million, up 14.0%, and ordinary profit was ¥3,538 million, up 14.6%, due to growth in principal products such as Entocort in overseas markets and lower selling, general and administrative expenses. Quarterly net income attributable to owners of the parent was ¥3,686 million, up 57.5%, due to the recognition of gains on the reversal of debt and the sale of investment securities as extraordinary income.」
Revenue declined year on year, while operating profit and ordinary profit increased due to growth in principal overseas products and lower selling, general and administrative expenses. Net income also increased with the addition of extraordinary income. - FY2021-Q2Lower revenue and operating profit, higher net incomeAnnual report
「Revenue for the second quarter of the current consolidated cumulative period was ¥26,809 million, down 11.6% year on year. Operating profit was ¥1,598 million, down 8.1%, and ordinary profit was ¥1,307 million, down 19.7%, due to foreign exchange losses resulting from the continued appreciation of the Swiss franc. Quarterly net income attributable to owners of the parent was ¥1,388 million, up 12.9%, due to the recognition of a gain on the reversal of debt as extraordinary income.」
For the first half, revenue, operating profit and ordinary profit declined, while quarterly net income attributable to owners of the parent increased due to a gain on the reversal of debt. - FY2021-Q1WorsenedAnnual report
「Revenue for the first quarter of the current consolidated cumulative period was ¥13,331 million, down 11.8% year on year. Operating profit was ¥1,060 million, down 20.3%, and ordinary profit was ¥634 million, down 59.3%, due to foreign exchange losses resulting from the continued appreciation of the Swiss franc. Quarterly net income attributable to owners of the parent was ¥974 million, down 15.0%, due to the recognition of a gain on the reversal of debt as extraordinary income.」
Revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent all declined year on year. Foreign exchange losses resulting from the appreciation of the Swiss franc were a factor behind the decline in ordinary profit. - FY2020Lower revenue, higher operating profit and lower net profitAnnual report
「As a result of these activities, revenue for the current consolidated fiscal year was ¥60,426 million, down 2.3% year on year. Supported by higher overseas sales of Asacol and reductions in selling, general and administrative expenses, operating profit was ¥4,094 million, up 9.6%, and ordinary profit was ¥3,879 million, up 17.7%. Meanwhile, net income attributable to owners of the parent was ¥2,925 million, down 15.3%, partly because extraordinary income had been recognized in the previous fiscal year.」
For the full year, revenue declined, while operating profit and ordinary profit increased due to higher overseas Asacol sales and lower selling, general and administrative expenses. Net income declined due to the absence of extraordinary income recognized in the previous fiscal year. - FY2020-Q3Lower revenue, higher operating profit and lower net profitAnnual report
「Against this backdrop, revenue for the third quarter of the current consolidated cumulative period was ¥46,303 million, down 1.9% year on year. Through efforts to use research and development expenses efficiently, operating profit was ¥3,382 million, up 10.5%, and ordinary profit was ¥3,086 million, up 9.5%. Meanwhile, quarterly net income attributable to owners of the parent was ¥2,339 million, down 19.3%, partly because extraordinary income had been recognized in the previous fiscal year.」
Revenue declined year on year, while operating profit and ordinary profit increased. Quarterly net income attributable to owners of the parent declined due to the absence of extraordinary income recognized in the previous fiscal year. - FY2020-Q2WorsenedAnnual report
「Against this backdrop, revenue for the second quarter of the current consolidated cumulative period was ¥30,317 million, down 0.5% year on year. Operating profit was ¥1,738 million, down 16.0%, and ordinary profit was ¥1,628 million, down 15.0%, due to the gradual decline in revenue and higher expenses including research and development costs. Quarterly net income attributable to owners of the parent was ¥1,230 million, down 46.0%, partly because extraordinary income had been recognized in the previous fiscal year.」
Revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent all declined year on year, with both revenue and profit continuing to fall. - FY2020-Q1WorsenedAnnual report
「Against this backdrop, revenue for the first quarter of the current consolidated cumulative period was ¥15,113 million, down 1.0% year on year. Operating profit was ¥1,329 million, down 18.6%, and ordinary profit was ¥1,556 million, down 10.6%, due to the gradual decline in revenue and higher expenses including research and development costs. Quarterly net income attributable to owners of the parent was ¥1,146 million, down 48.9%, partly because extraordinary income had been recognized in the previous fiscal year.」
Revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent all declined year on year. - FY2019WorsenedAnnual report
「Revenue for the current consolidated fiscal year was ¥61,831 million, down 4.2% year on year. Operating profit was ¥3,737 million, down 22.6%; ordinary profit was ¥3,295 million, down 35.2%, due to foreign exchange losses resulting from the continued appreciation of the Swiss franc; and net income attributable to owners of the parent was ¥3,454 million, down 16.9%, with all three profit figures declining year on year.」
Full-year revenue, operating profit, ordinary profit and net income attributable to owners of the parent all declined year on year. - FY2019-Q3WorsenedAnnual report
「Against this backdrop, revenue for the third quarter of the current consolidated cumulative period was ¥47,215 million, down 4.9% year on year. Operating profit was ¥3,061 million, down 33.3%; ordinary profit was ¥2,819 million, down 42.3%, due to foreign exchange losses resulting from the continued appreciation of the Swiss franc; and quarterly net income attributable to owners of the parent was ¥2,900 million, down 26.7%.」
Revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent all declined year on year, continuing the downward profit trend through the previous quarter. - FY2019-Q2Lower revenue and operating profit, higher net income due to settlement proceedsAnnual report
「Revenue for the second quarter of the current consolidated cumulative period was ¥30,483 million, down 6.0% year on year. Operating profit was ¥2,069 million, down 13.5%, and ordinary profit was ¥1,914 million, down 24.5%, due to foreign exchange losses resulting from the appreciation of the Swiss franc. Meanwhile, quarterly net income attributable to owners of the parent was ¥2,280 million, up 7.2%, due to the recognition of extraordinary income.」
Revenue, operating profit and ordinary profit declined year on year, while quarterly net income attributable to owners of the parent increased due to the recognition of extraordinary income, including settlement proceeds received. - FY2019-Q1Lower revenue, sharp increase in profitAnnual report
「Against this backdrop, revenue for the first quarter of the current consolidated cumulative period was ¥15,259 million, down 4.5% year on year. Operating profit was ¥1,632 million, up 173.5%, and ordinary profit was ¥1,741 million, up 162.4%, supported by solid overseas performance, efficient use of expenses and the deferral of part of research and development expenses to the second quarter and beyond. Quarterly net income attributable to owners of the parent was ¥2,244 million, up 241.3%, due to the recognition of extraordinary income.」
Revenue declined, while operating profit, ordinary profit and quarterly net income attributable to owners of the parent increased substantially due to overseas performance, more efficient use of expenses, the timing of research and development expense recognition and the recognition of extraordinary income. - FY2018AdvancedAnnual report
「As a result of these activities, revenue for the current consolidated fiscal year was ¥64,568 million, down 0.4% year on year. However, supported by solid overseas performance and efforts to use expenses including research and development costs efficiently, operating profit was ¥4,830 million, up 6.4%; ordinary profit was ¥5,089 million, up 14.7%; and net income attributable to owners of the parent was ¥4,157 million, up 17.3%, with all three profit figures increasing year on year.」
Revenue declined slightly, but operating profit, ordinary profit and net income attributable to owners of the parent all increased year on year. - FY2018-Q3AdvancedAnnual report
「Against this backdrop, revenue for the third quarter of the current consolidated cumulative period was ¥49,644 million, up 1.2% year on year. Supported by solid overseas performance and lower selling, general and administrative expenses, operating profit was ¥4,587 million, up 26.0%; ordinary profit was ¥4,890 million, up 39.6%; and quarterly net income attributable to owners of the parent was ¥3,955 million, up 37.6%.」
Revenue increased for the first three quarters, while operating profit, ordinary profit and quarterly net income attributable to owners of the parent increased year on year due to solid overseas performance and lower selling, general and administrative expenses. - FY2018-Q2WorsenedAnnual report
「Against this backdrop, revenue for the second quarter of the current consolidated cumulative period was ¥32,412 million, up 0.3% year on year. Operating profit was ¥2,393 million, down 24.0%, and ordinary profit was ¥2,534 million, down 17.8%, partly due to higher expenses including research and development costs. Quarterly net income attributable to owners of the parent was ¥2,128 million, up 6.1%, due to the recognition of a gain on the sale of investment securities as extraordinary income.」
Revenue increased, while operating profit and ordinary profit declined due to higher expenses including research and development costs. Quarterly net income attributable to owners of the parent increased due to a gain on the sale of investment securities. - FY2018-Q1WorsenedAnnual report
「Against this backdrop, revenue for the first quarter of the current consolidated cumulative period was ¥15,970 million, down 3.1% year on year. Operating profit was ¥597 million, down 65.3%; ordinary profit was ¥663 million, down 63.8%; and quarterly net income attributable to owners of the parent was ¥657 million, down 50.5%. In addition to the gradual decline in revenue, the company discontinued all ongoing research and development following the termination of its licensing agreement with EA Pharma Co., Ltd. concerning the novel proton pump inhibitor Z-215, and recognized the associated liquidation costs as research and development expenses in the first quarter.」
Revenue fell 3.1% year on year, while the discontinuation of research and development and liquidation costs following the termination of the Z-215 licensing agreement also contributed to substantial declines in operating profit, ordinary profit and quarterly net income attributable to owners of the parent. - FY2017Higher Revenue and Lower Operating ProfitAnnual report
「Revenue was ¥64,849 million, up 3.8% year on year; operating profit was ¥4,541 million, down 0.5%; ordinary profit was ¥4,438 million, down 0.3%; and net income attributable to owners of the parent was ¥3,544 million, up 0.9%.」
For the full year, revenue and net income attributable to owners of the parent increased, while operating profit and ordinary profit decreased year on year. - FY2017-Q3WorsenedAnnual report
「Against this backdrop, revenue for the third quarter of the current consolidated cumulative period was ¥49,043 million, up 4.2% year on year. As expenses including research and development costs increased substantially, operating profit was ¥3,641 million, down 4.0%; ordinary profit was ¥3,502 million, down 7.0%; and quarterly net income attributable to owners of the parent was ¥2,873 million, down 13.8%.」
Revenue increased, while operating profit, ordinary profit and quarterly net income attributable to owners of the parent all decreased year on year due to higher expenses including research and development costs. - FY2017-Q2AdvancedAnnual report
「Against this backdrop, revenue for the second quarter of the current consolidated cumulative period was ¥32,313 million, up 6.5% year on year. Operating profit was ¥3,148 million, up 48.9%; ordinary profit was ¥3,083 million, up 94.6%; and quarterly net income attributable to owners of the parent was ¥2,006 million, up 24.1%.」
Revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent for the six months ended 30 September increased year on year. - FY2017-Q1AdvancedAnnual report
「Against this backdrop, revenue for the first quarter of the current consolidated cumulative period was ¥16,488 million, up 12.0% year on year. Operating profit was ¥1,720 million, up 67.4%; ordinary profit was ¥1,832 million, up 208.1%; and quarterly net income attributable to owners of the parent was ¥1,328 million, up 49.0%.」
Revenue, operating profit, ordinary profit and quarterly net income attributable to owners of the parent all increased year on year in the first quarter. - FY2016First statedAnnual report
「Revenue was ¥62,475 million, up 2.4% year on year; operating profit was ¥4,565 million, up 70.4%; ordinary profit was ¥4,450 million, up 60.7%; and net income attributable to owners of the parent was ¥3,513 million, up 37.4%.」
These figures are reported as the consolidated results for the fiscal year.